Tyrosine kinase inhibitors (TKIs) have potent effects on malignant cells, and they also target kinases in normal cells, which may have therapeutic implications. Using a collection of 55 leukemia patients treated with TKI therapy (chronic myeloid leukemia, n ¼ 47; acute lymphoblastic leukemia, n ¼ 8), we found that dasatinib, a second-generation broad-spectrum TKI, induced a rapid, dose-dependent and substantial mobilization of non-leukemic lymphocytes and monocytes in blood peaking 1-2 h after an oral intake and the blood counts closely mirrored drug plasma concentration. A preferential mobilization was observed for natural killer (NK), NK T, B and gd þ T cells. Mobilization was coupled with a more effective transmigration of leukocytes through an endothelial cell layer and improved cytotoxicity of NK cells. Platelet numbers decreased markedly after the drug intake in a proportion of patients. Similar effects on blood cell dynamics and function were not observed with any other TKI (imatinib, nilotinib and bosutinib). Thus, dasatinib induces a unique, rapid mobilization and activation of cytotoxic, extravasation-competent lymphocytes, which may not only enhance antileukemia immune responses but can also be causally related to the side-effect profile of the drug (pleural effusions, thrombocytopenia).
INTRODUCTION
Tyrosine kinase inhibitors (TKIs) are the first molecularly targeted drugs that have entered into a widespread clinical use in treating selected malignancies, such as kidney, lung and blood cancers. In particular, TKIs have significantly improved the outcome of chronic myeloid leukemia (CML) and Philadelphia-chromosomepositive (Ph þ ) acute lymphoblastic leukemia (ALL) and currently are the standard first-line therapy for these disorders. [1] [2] [3] [4] [5] In addition to imatinib, a first-generation TKI, second generation TKIs dasatinib and nilotinib, have been introduced for patients with imatinib resistance or intolerance and have further improved treatment results. [6] [7] [8] [9] The kinase inhibition profile of second-generation TKIs, dasatinib in particular, is broad [10] [11] [12] [13] and also results in alterations in the function of normal cells, which may cause unexpected off-target phenomena. Recently, we and others observed that in a subgroup of patients, dasatinib therapy induced an absolute, oscillating blood lymphocytosis. [14] [15] [16] [17] [18] [19] [20] [21] Blood lymphocytes had an activated, large granular lymphocyte (LGL) morphology and the expansion consisted of clonal cytotoxic memory cells present already at the time of diagnosis and before the initiation of any TKI therapy.
14 Strikingly, lymphocytosis was correlated with exceptionally good therapy responses in patients with advanced leukemia, and with autoimmune adverse effects (such as pleural effusions and colitis). 16, 19 Although the dasatinib-induced LGL lymphocytosis appeared clinically meaningful, its mechanisms are not well understood. We therefore collected a set of 55 Ph þ leukemia patients treated with four different TKIs (dasatinib, imatinib, nilotinib and bosutinib) and analyzed numbers, phenotypes and functional properties of blood cell subpopulations in samples collected before and after a single oral drug dose.
METHODS

Study patients
A total of 55 consecutive Ph þ leukemia patients treated either with dasatinib (n ¼ 37), imatinib (n ¼ 8), nilotinib (n ¼ 8) or bosutinib (n ¼ 2) were included in the study (see Supplementary Table 1 for patient characteristics). The study was conducted in accordance with the Declaration of Helsinki principles and was approved by the Helsinki University Central Hospital Ethics committee. Written informed consents were obtained from all patients before sample collection.
Blood samples and immunophenotyping
Blood samples were collected in the morning before the patient took his/ her daily drug dose and after drug intake at specified time points. From all patients, samples were taken when drug plasma concentrations were at their peak levels (1 h after dasatinib intake and 2 h after imatinib, nilotinib or bosutinib intake). In addition, from 18 dasatinib-treated patients samples were collected at 1, 2 and 4 h after the drug intake, and similar data were collected from one healthy control after 100 mg of dasatinib. In one index patient, a 48 h follow-up was performed (samples taken at 0, 0.5, 1, 2, 4, 8, 12 and 24 h after single 100 mg dasatinib dose and similar follow-up next day). Samples were also collected from two imatinib, two nilotinib and two bosutinib patients up to 8 h after a single oral dose (0, 1, 2, 4, 6 and 8 h).
For functional analysis, fresh peripheral blood (PB) ethylenediaminetetraacetic acid (EDTA) samples were collected from 18 CML patients (treated with dasatinib, n ¼ 10; imatinib, n ¼ 3; or nilotinib, n ¼ 5) and healthy controls (n ¼ 6). Plasma and mononuclear cells (MCs) were separated by Ficoll gradient centrifugation (GE Healthcare, Buckinghamshire, UK).
Immunophenotyping of blood and endothelial cells was carried out with multicolor flow cytometry (FACS Canto II; BD Biosciences, San Jose, CA, USA). More detailed information can be found in the Supplementary Information.
Drug concentration
Plasma dasatinib concentrations were determined by high-performance liquid chromatography/mass spectroscopy as described previously. 22 Plasma imatinib and nilotinib concentrations were measured by a sensitive ultra-performance liquid chromatography-tandem mass spectroscopy, as described previously. 23 
Cytokine array
Plasma cytokine profile was analyzed using a Human Cytokine 25-Plex Panel (Invitrogen, Camarillo, CA, USA) according to the manufacturer's instructions (see Supplementary Methods).
Gene expression analysis
Gene expression changes were measured with the Agilent 4 Â 44k Whole Human Genome Microarray (Agilent Technologies, Santa Clara, CA, USA). In brief, first CD8 þ T cells were selected from blood samples from five dasatinib-treated patients using positive selection with magnetic CD8 MicroBeads (Miltenyi Biotech GmbH, Teterow, Germany). Selections had purities 490% according to fluorescence-activated cell sorting analyses. RNA was isolated with Nucleospin RNA II Kit (Macherey Nagel, Dü ren, Germany) before gene expression analysis.
The expression data were first preprocessed with the Agilent Feature Extractor (version 10.7.3.1) and all probes were re-annotated with Ensembl genomic database (version 58) (reference: PMID: 21045057). The expression values belonging to the lowest 5% were removed to reduce noise. Gene expression values were calculated as the median of probes mapping to the same gene. The fold changes (FCs) were calculated by comparing each patient's 1 h sample to the 0 h sample. All analyses were performed with the freely available Anduril framework. 24 Cytotoxicity assay K562 cells were stained with Violet cell proliferation stain (Invitrogen) according to manufacturer's instructions. Next day, freshly isolated PBMCs from both pre-and post-TKI samples were cocultured with K562 in effector-to-target ratio (E:T) 0:1, 5:1, 10:1 and 20:1. Effectors were calculated from both total PBMCs and according to the NK-cell percentage. Furthermore, NK cells were purified from fresh PBMCs by using Invitrogen's Dynabeads Untouched Human NK Cell Kit (Invitrogen, Carlsbad, CA, USA). The purified NK cells (purity 495%) were used as effectors in ratios 0:1, 5:1 and 10:1. After 6 h of coculturing, the cells were stained with LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen). CountBright beads (Invitrogen) were added to each tube and 5000 beads were counted. The gate was set on violet K562 cells and the percentage of live K562 cells was calculated. In parallel, fresh PBMCs were stimulated with K562 (in ratio 10:1) for 6 h in the presence of the degranulation markers CD107a/b. The cells were stained with CD45, CD3, CD56 and CD16 (Invitrogen), and analyzed with FACSAria (BD Biosciences).
In vitro flow assays
PBMCs were isolated from patients before and 1 h after dasatinib or 2 h after imatinib intake and re-suspended in the binding medium (Hank's balanced salt solution with calcium and magnesium þ 1% human serum albumin). The flow assays were performed as described, 25, 26 with a few modifications. Human umbilical vein endothelial cells (passages 2-4) were cultured into confluence in plastic flow chamber channels (1m-Slide VI ibiTreat; Ibidi Integrated BioDiagnostics, Martinsried, Germany), and induced with tumor necrosis factor-a (100 U/ml for rolling and adhesion assays and 500 U/ml for the transmigration assays) for 4 h. The leukocytes were then perfused through the channels at 0.75 dyn/cm 2 shear at room temperature. Rolling and adhesion were determined after a 3 min perfusion. For transmigration studies, a 5 min perfusion of cells was followed by a 10 min perfusion with the flow buffer. The interaction of leukocytes with endothelial cells was recorded with a phase-contrast videomicroscope from five pre-defined microscopic fields.
The numbers of rolling, adherent (bound phase-bright cells) and transmigrated (phase-dark cells) cells were counted from the videos offline, as described earlier. 25, 27 The transmigration percentage is obtained by dividing the number of transmigrated cells with all the interacting (adhesive plus transmigrated) cells. The numbers of interacting cells in the paired samples from each patient were compared by assigning value 100% to the control sample in each case. We scored 191±31 (mean±s.e.m., n ¼ 6) transmigrating, and 1169±174 (mean±s.e.m., n ¼ 6) adherent cells, corresponding to 67 ± 11 and 412 ± 61 transmigrated and adherent cells per mm 2 , respectively, in each control capillary. Thus, in the control capillaries on an average 14% of the bound leukocytes had transmigrated at the 15-min time point.
Statistical analysis
Tests for differences in distributions, repeated measures and correlations were carried out with both parametric (T-test, analysis of variance) and non-parametric methods (Wilcoxon's, Kruskal-Wallis, Mann-Whitney, Spearman's rank tests), as appropriate. P-values o0.05 were considered statistically significant and calculated using PASW Statistics (version 18.0).
RESULTS
Rapid changes in blood counts after intake of dasatinib Our index patient is a 44-year-old male in complete remission from ALL characterized by a dasatinib-sensitive RCSD1-ABL1 fusion protein derived from a t(1;9)(q24;q34) translocation. 28 After an intake of 100 mg dasatinib, a rapid increase in blood leukocyte, lymphocyte and monocyte counts were observed, with peak counts 1-2 h after drug intake ( Figure 1a) . The blood count changes were similar and reproducible at two consecutive days ( Figure 1a ). Similar changes during a 4-h follow-up were also observed in a healthy control after an intake of 100 mg dasatinib ( Figure 1b) .
We next collected serial blood counts from a group of 18 patients with a 4-h follow-up ( Figure 1c ) and from 37 patients with a 1-h follow-up (a total of 88 paired 0-and 1-h follow-up samples; Figure 2 ) (patient characteristics are given in Supplementary Table 1 ). The alterations in blood counts were expressed as FCs by comparing the absolute follow-up values to the absolute baseline values to transform the blood count changes to a comparable metric. The most marked mobilization was observed in lymphocyte counts with mean FC (mFC) at 1 h after dasatinib intake of 2.42 (range 0.89-6.75, Po0.0001) and at 2 h of 2.25 (range 1.14-4.62, Po0.0001), with a considerable betweenpatient variation (Figures 1c and 2c ). Monocyte (mFC 1.67, range 0.95-3.44, Po0.0001) and neutrophil (mFC 1.22, range 0.76-2.07, Po0.0001) changes were more modest. Platelet counts decreased rapidly at 1-2 h after dasatinib treatment (mFC at 1 h 0.89, range 0.3-1.08, Po0.0001), but again with marked between-patient variation (Figures 1c and 2b) .
Dasatinib-induced increases in lymphocyte counts were clinically significant. A total of 14/37 (38%) patients developed absolute lymphocytosis at 1 h (lymphocyte counts exceeding the laboratory upper normal level of 3.6 Â 10 9 /l) with highest counts up to 10.3 Â 10 9 /l (6.75 FC; Figure 2c ). In a subgroup of patients, the decrease in platelet counts was pronounced. In a total of 11/37 (30%) patients, the platelet count decreased below the laboratory lower normal level of 150 Â 10 The FCs in absolute blood lymphocyte counts between time points 0 and 1 h correlated positively with corresponding FCs in monocyte (r S ¼ 0.52, Po0.0001) and neutrophil counts (r S ¼ 0.42, Po0.0001) and negatively with platelet counts (r S ¼ À 0.51, Po0.001), putatively implying a shared mechanism of action.
Leukocyte mobilization is specific for dasatinib No significant changes in blood counts were observed for two imatinib, two nilotinib and two bosutinib patients studied during an 8 h follow-up period (samples taken at 0, 1, 2, 4 and 8 h) after a single drug dose (400 mg imatinib, 300 mg nilotinib and 500 mg bosutinib) (data not shown) nor in six additional imatinib and six nilotinib patients at 0 and 2 h time points (Figures 2a, b and d, f). Incidentally, our index patient with absolute lymphocytosis on dasatinib was switched to imatinib therapy because of intolerable adverse effects and no lymphocyte mobilization post-imatinib was observed. Thus, the blood count changes observed are not patient-related or a TKI class effect, but dasatinib-specific.
Lymphocyte mobilization closely mirrors dasatinib plasma concentration The peak drug concentration in plasma occurs already at 1-2 h post-dasatinib intake followed by a rapid decline thereafter with a half-life of 3-4 h. 29 To assess the relation between drug concentration and blood counts, we measured dasatinib plasma concentration from 30 patients using high-performance liquid chromatography/tandem mass spectroscopy. In our index patient and in the healthy control, blood lymphocyte counts closely followed dasatinib plasma concentration (Figures 3a and b) . Similarly, on an individual patient basis the correlation between lymphocyte counts and dasatinib plasma level was very good (r S ¼ 0.88, P ¼ 0.002; Figure 3c , index patient). However, among different patients the correlation was significantly weaker (r S ¼ 0.25, P ¼ 0.028; Figure 3d , all patients), indicating marked variation in the relation between dasatinib plasma concentration and its effect on the blood lymphocyte counts. At the median dasatinib concentration of 0.062 mM at 1 h after dasatinib intake, the corresponding lymphocyte count varied from 1.1 to 8.0 Â 10 9 /l between different patients (Figure 3d ). Higher post-dasatinib plasma concentrations at 1 h tended to result in larger lymphocyte FC values (r S ¼ 0.50, P ¼ 0.0001).
In line with the good within-patient correlation between the drug plasma concentration and blood lymphocyte counts, there was a clear dasatinib dose response in lymphocyte counts in a dose-escalation experiment performed on consecutive days with two patients (Figure 3e ). These data imply that dasatinib-induced lymphocyte mobilization is drug dose controllable. However, during a long-term follow-up of these two patients, the relation of the daily 100 mg dasatinib dose to the lymphocyte count was not always constant (Figure 3f ), implying the influence of other factors on the lymphocyte count.
Preferential mobilization of LGL cells and B cells
To determine the composition of mobilized lymphocyte pool, blood samples from 24 dasatinib-treated patients were analyzed with six-color flow cytometry at 0 and 1 h time points. In addition, as LGL-type lymphocytosis has previously been described in dasatinib patients, 16, 19, 21, 30 the morphology of lymphocytes was analyzed from May-Grü nwald-Giemsa-stained blood smears (n ¼ 28). As a comparison, immunophenotyping and LGL evaluation was performed from six imatinib-, four nilotinib-and two bosutinib-treated patients at 0 and 2 h time points.
NK cells (CD3 À CD16/56 þ ) and B cells (CD19 þ ) showed the highest relative increase in total lymphocyte pool with a mFC of 1.4 (range 0.8-2.1, P ¼ 0.00005) and 1.8 (0.7-5.2, Po0.0001), respectively (Figure 4a) . In absolute numbers, increase was Figure 2 . Changes in total leukocyte and thrombocyte counts and in blood lymphocyte composition are dasatinib specific. Blood samples were collected before and after 1 h from the intake of dasatinib (n ¼ 88) or after 2 h from the intake of other TKIs (imatinib, n ¼ 11; nilotinib, n ¼ 11; and bosutinib, n ¼ 2). The FCs of (a) total leukocyte, (b) thrombocyte, (c, d) absolute lymphocyte subclass and (e, f) relative lymphocyte subclass counts are shown. The black lines denote the median values. Figure 1a) . It is worth noting that, in some patients, the absolute LGL cell count increased up to 8.0-fold from the baseline level (mFC 3.4, range 1.3-8.0, P ¼ 0.0001) (Figure 4b) . In other TKItreated patients, no significant changes in the composition of lymphocyte pool were observed (Figures 4a and b , panels on the right side).
Predictive factors and prognostic value of lymphocyte mobilization No correlation between the extent of lymphocyte mobilization and clinical characteristics of the patients (for example, age, sex, time on therapy) was found (results not shown). Interestingly, cytomegalovirus-seropositive patients had a higher median lymphocyte counts at 1 h compared with cytomegalovirus-negative patients (4.8 vs 2.0±10 9 /l, P ¼ 0.016). Furthermore, patients with the highest absolute lymphocyte counts at 1 h had the lowest Treg levels, suggesting that Treg-mediated regulatory mechanisms may be compromised (r S ¼ À 0.75, Po0.0001; Supplementary Figure 1b) . However, no correlation was found between Treg numbers and magnitude of lymphocyte increase (FC) (Supplementary Figure 1c) .
To assess the prognostic value of lymphocyte mobilization, the patients were divided into two groups based on the mFC value: high mobilizers (mFC 43, 7 patients) and low mobilizers (mFC o3, 30 patients). All high mobilizer patients experienced a rapid and deep reduction in leukemic tumor burden after the start of dasatinib: 6/7 patients (86%) achieved complete disease eradication as measured by PCR (complete molecular response) and 1 patient achieved a substantial decrease in the tumor burden (major molecular response) within 6 months of therapy start. In contrast, only 1/30 patients (3%) with a low mFC achieved a complete molecular response within 6 months. Thus, the extent of lymphocyte mobilization after an oral dose of dasatinib may have prognostic significance.
Changes in gene expression and cytokine profile A differential gene expression analysis was performed from CD8 þ sorted T cells at 0 and 1 h time points with a 44 k oligonucleotide array (n ¼ 5). A total of 30 upregulated (42-fold) genes were found at least in four out of five patients, including HSPA12A (Hsp70 family member), GRM4 (glutamate receptor, metabotropic 4), IDO-1 and -2 (indoleamine 2,3-dioxygenase 1 and 2), FCRL5 (Fc receptor-like 5), TLR10 (Toll-like receptor 10), complement proteins C1qB and C1qA, and interferon-g-inducible gene CXCL11 (Table 1) . Differentially downregulated genes included GNG11 (G-protein gamma-11 subunit), TRIM58 (Tripartite motif-containing 58), SPARC (osteonectin) and ITGB3 (CD61) ( Table 1) .
Plasma levels of 25 cytokines were measured at 0 and 1 h time points from 23 dasatinib-treated patients, but no significant differences were observed (data not shown). However, levels of the chemotactic cytokines CXCL10 (IP-10) and CXCL-9 (MIG) correlated with the proportion of CD57-expressing cells (r S ¼ 0.70, P ¼ 0.003 and r S ¼ 0.69, P ¼ 0.004, respectively) and in some patients these cytokines were significantly increased at 1 h time point consistent with an interferon-g-type immune activation.
Exposure to dasatinib in vivo enhances the cytotoxicity of circulating NK cells TKIs have been shown to inhibit NK-cell cytotoxicity in vitro. [31] [32] [33] To analyze the situation in patients and the effect of lymphocyte mobilization, we studied the function of NK cells pre-and post-TKI intake (1-2 h in vivo exposure). When PBMC fraction was used as an effector population (E:T ratio 20:1), the median percentage of dead K562 cells was 18% in patient samples taken before and 32% taken after dasatinib intake (P ¼ 0.004; Figure 5a ). No differences in NK-cell cytotoxicity were observed after imatinib (11 vs 8%; Figure 5b ) or nilotinib (10 vs 10%; Figure 5c ) intake. The cytotoxicity of the PBMC fraction before dasatinib intake was similar as in healthy controls (P ¼ 0.12), whereas 1 h after dasatinib intake, the cytotoxic capacity was increased and significantly higher than in healthy volunteers (P ¼ 0.0225; Figure 5a ). The results were confirmed with purified NK cells: the median percentage of dead K562 cells was 12% in pre-dasatinib and 29% in post-dasatinib samples (E:T ratio 10:1, P ¼ 0.06), whereas no differences were noticed with imatinib (30 vs 28%) or nilotinib (14 vs 15%) patients (Figures 5b and c) . The median percentage of dead K562 cells after incubation with purified NK cells from healthy volunteers was 20%.
To study if the higher cytotoxicity capacity seen in samples taken 1 h after dasatinib intake was caused by an increased number of K562-reactive NK cells, degranulation assays were performed in parallel. The results demonstrate that the proportion of degranulated NK cells after K562 stimulation between healthy controls and patients on dasatinib therapy (both pre-and post-TKI) were equal (P ¼ 0.98). However, when the absolute number of CD107ab þ NK cells was calculated, there was a trend towards higher number of CD107ab þ NK cells in dasatinib-treated patients, especially in the samples taken 1 h after drug intake (Figure 5d) , indicating that the increased number of NK-LGLs seen after dasatinib intake possess a higher cytotoxic capacity, resulting in higher killing percentage.
Dasatinib induces leukocyte transmigration
To further assess the functional properties of the mobilized lymphocytes, an in vitro flow chamber assay and real-time videomicroscopy was used to analyze leukocyte rolling, adhesion and transmigration through a vascular endothelial cell layer. In dasatinib-treated patients, lymphocyte rolling on and adhesion to human umbilical vein endothelial cell layer did not differ between the samples taken before and after the drug intake ( Figure 6a ). However, in samples taken 1 h after the drug intake, the leukocyte migration through the endothelial cell layer was significantly increased (Figures 6a, c and d) . A similar increase (3.8-fold) in the transmigration after the dasatinib intake was also seen in a healthy control (results not shown). No alterations in the transmigration were observed in imatinib-treated patients (Figure 6b ).
To study whether in vitro treatment with dasatinib affects leukocyte migration, PBMCs from three healthy controls and five CML patients were treated for 1 h with 50 nM dasatinib. No changes in leukocyte transmigration were observed after in vitro treatment (Supplementary Figure 2) . Similarly, in vitro treatment of endothelial cells with dasatinib had no effect on leukocyte transmigration (Supplementary Figure 3e) .
PBMCs were stained with antibodies against various adhesion molecules (selectins, integrins and others) and chemokine receptors to understand whether changes in adhesion molecule profile would explain the increased transmigration capacity. In patients with a 41.25-fold increase in leukocyte counts, significantly more CD162, CD11a, CD18, a4-integrin, b7-integrin and CD44 þ cells were found 1 h after dasatinib treatment (Supplementary Table 2 ). Moreover, there was a 1.7-fold increase in the cells expressing high level of CD11a, and a 1.8-fold increase in the cells expressing high levels of CD18 1 h after dasatinib treatment (Figure 6e and Supplementary Table 3 ). Further analysis with multicolor flow cytometry showed that in both T-cell (CD3 þ CD4 þ and CD3 þ CD8 þ ) and NK-cell populations, the proportion of CD11a high/CD18high-expressing cells increased in the 1 h samples (data not shown). None of these alterations in adhesion molecule expression were found in the dasatinib-treated patients with a mild leukocytosis (o1.25 FC) or in imatinib-treated patients (Supplementary Tables 2 and 3) .
In vitro treatment of PBMCs with dasatinib had no effect on integrin expression (Supplementary Table 4 ). This suggests that the increased CD11a/CD18 expression at 1 h samples is due to preferential mobilization of cells with an activated phenotype in concordance with the immunophenotyping results described above (see Figure 4) . Furthermore, in vitro treatment with dasatinib did not markedly change the adhesion molecule expression (ICAM-1, VCAM-1, CD31, CD62E, CD73 and CD44) on endothelial cells and it did not result in increased transmigration of leukocytes (Supplementary Figure 3 and results not shown) .
DISCUSSION
The notion of the dual mode of action of TKIs-direct antitumor effect accompanied by indirect enhancement of antitumor immunity-has gained increasing attention. Recently, imatinibinduced inhibition of the immunosuppressive protein indoleamine 2,3-dioxygenase in gastrointestinal stromal tumor tumors was shown to result in CD8 þ T activation and induction of Treg apoptosis both in mouse and human tumors, which significantly contributed to the efficacy of the drug. 34 Similarly in a mastocytoma mouse model, the antitumor effects of dasatinib treatment were dependent on T-cell-mediated immune responses. 35 Furthermore, in dasatinib-treated CML and Ph þ ALL patients, an oscillating, absolute LGL lymphocytosis has been observed, and has correlated with good therapy responses and autoimmune phenomena (pleural effusions, colitis), but the cellular and molecular mechanisms have remained elusive. [14] [15] [16] [17] [18] [19] Our data indicate that the curious fluctuation of lymphocyte counts observed in previous studies predominantly reflects the time of blood sampling. Dasatinib induced a rapid increase in blood leukocyte, lymphocyte and monocyte counts after a single oral dose, with peak counts 1-2 h after the drug intake and a restoration to pre-dose levels within 12 h. A morphological analysis of blood smears showed the preferential mobilization of The number patients in which the specified gene was up-or downregulated out of total five patients studied.
Dasatinib induces lymphocyte mobilization S Mustjoki et al LGL morphology with up to 8.0-fold increase in absolute numbers. By immunophenotyping, the LGL cells were cytotoxic effector cells (predominantly NK cells, CD57 þ /HLA-DR þ T cells and gd þ T cells) and also the gene expression analysis from CD8 þ cells showed upregulation of many genes important in immune activation, such as chemotactic CXCL11 and TLR10, belonging to Toll-like receptor family. In addition to numerical changes, also the cytotoxic function of NK cells significantly improved in samples taken 1 h after dasatinib intake. Taken together, these changes in several types of immune effector cells may boost the immune system on a daily basis after each drug dose and in the long-term lead to enhanced antitumor immunity and contribute to exceptional therapy responses as observed earlier in dasatinib-treated patients with LGL lymphocytosis. The between-patient variation in dasatinib dose/mobilization magnitude ratio was highly variable, implying patient-specific determinants in lymphocyte mobilization. Only cytomegalovirus seropositivity was linked to the magnitude of mobilization, suggesting that the composition of the lymphocyte clonal pool and absolute numbers of distinct clones could be determinants of mobilization. This is of interest, as the results also suggested that the magnitude of mobilization is related to the treatment response.
The adverse-effect profile of dasatinib is distinct from other TKIs. Pleural effusions occur in 10-20% of dasatinib patients and may have an immune-mediated etiology. [36] [37] [38] [39] We have previously shown that lymphocyte infiltrations with similar phenotype and clonotype as in PB can be found in pleural fluid samples, 16 suggesting that the circulating lymphocytes transmigrate in pleural space. This fits well with data in this study showing that leukocyte transmigration through an endothelial cell layer was significantly increased in samples taken 1 h after dasatinib intake. The observed increased expression of activated LFA-1 and b1-integrins in PBMCs can be directly involved in the enhanced transmigration. In addition to pleural effusions, thrombopenia has been related to dasatinib therapy more often compared to treatment with other TKIs and the reason for this has been unclear. 3 In our cohort, 30% of patients had a clinically significant decrease in platelet counts 1-2 h after dasatinib dosing, and in some patients, the effect was very dramatic (down to À 70% or 32 Â 10 9 /l). The T-cell activation may be related to platelet decrease as CD40L þ T cells induce platelet activation through a contact-mediated, CD40-dependent pathway, resulting in RANTES (regulated and normal T-cell expressed and secreted) release and immune response amplification. 40 These platelet changes may also have an effect on blood coagulation, which needs to be taken into account when treating patients with a very low pre-dose platelet count. However, the decrease in platelet counts was transient and values were back to normal level usually 4 h after the dasatinib dose.
The kinase(s) targeted by dasatinib, resulting in lymphocyte mobilization, are unknown. Large databases on kinase inhibitor specificities have recently been published enabling deduction of candidate kinase targets. 41, 42 Based on the Fox Chase data set, 41 kinases potently and exclusively inhibited by dasatinib, but not by imatinib, nilotinib or bosutinib, include NEK11, ALK1/ACVRL1, SRMS, EPHA1, NLK and RIPK2 kinases. Of these, EPHA1 had the lowest residual kinase activity score (2.7% at 0.5 mM TKI) and a low selectivity score, indicating inhibition by only a limited number of drugs. The EphA and ephrin-A families of cell-surface proteins have been shown to have an important role in modulating the adhesion of non-lymphoid and lymphoid cells through the regulation of integrin activity. [43] [44] [45] Furthermore, similar kind of rapid mobilization of cytotoxic lymphocytes into circulation has been observed during physical exercise, [46] [47] [48] putatively related to increased catecholamine levels. 49 Interestingly, exercise also induces a preferential mobilization of cells with high cytotoxic and tissue-migrating potential. 48, 49 It has been shown that SRC kinase binds to the b2-adrenergic receptor via phospho-Tyr-350 and is required for the receptor de-sensitization. 50 Thus, dasatinibinduced SRC inhibition could impair b-adrenergic receptor desensitization, leading to overstimulation and catecholamine release. However, further studies are needed to assess the possible role of EPHA1, adrenergic system and other candidate kinases in lymphocyte mobilization.
As a conclusion, the results provide evidence for the first time of the feasibility of pharmacological mobilization and activation of lymphocytes in blood by tyrosine kinase inhibition, akin to granulocyte mobilization by the cytokine granulocyte-colonystimulating factor. TKI dasatinib had a clinically significant direct effect on the immune effector cells, resulting in rapid lymphocyte mobilization, activation and transmigration. Strikingly, all these effects were specific for dasatinib and not observed with any other TKIs, ruling out a class effect. Furthermore, the lymphocyte mobilization was closely dose-controllable and not only observed in leukemia patients but also occurred in a healthy control. The observed rapid lymphocyte mobilization and activation may explain the typical side-effect profile of the drug (such as pleural effusions), but it could also have therapeutic implications in enhancing immune responses in both malignant and nonmalignant diseases.
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